- Total Pro Portfolios with HYTM:
- Gartmore Small Cap A (GSXAX)
- show more
- 1
- Total Do-It-Yourself Portfolios with HYTM:
- robert nyilas Portfolio 1
- gil cohen Portfolio 1
- 2007 year one
- hany 1
- B Michels Portfolio 1
- Brad Kastan Portfolio 1
- calvin casey Portfolio 1
- svgq4life Portfolio 1
- mink port1
- Gene Macial's Inside Wall Street Stock Picks
- wallstguy@hotmail.com Portfolio 1
- bill 1
- tplyler Portfolio 1
- aries Portfolio 1
- BENITRANS IH
- Tpost022 Portfolio 1
- Barron's Insider Purchases 04-19-2008
- show more
- 34
- new guy
- Capital Appreciation
- hobart webster Portfolio 1
- Keith Walter Portfolio 1
- Lucas Hand Portfolio 1
- Portfolio Two
- luna Portfolio 1
- joseywales Portfolio 1
- JTMedina
- jamesali Portfolio 1
- mileslb Portfolio Scottrade
- Amateur
- JAG1969 Portfolio 1
- S-0050
- ESTAVENOW#4
- Barron's Insider Purchases 04-12-2008
- Henry@UBS
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:John Trevor |
Date:04 15 07 |
With alcohol and drug abuse continuing to be a nationwide scourge, some investors are hopeful that Hythiam's PROMETA may help curb the problem. Hythiam (HYTM ) licenses PROMETA to treatment centers, managed-care providers, and government agencies. Using a combination of nutritional supplements and Food & Drug Administration-approved oral and intravenous medications, PROMETA can reduce cravings and promote abstinence, say analysts. Although still controversial, "early results from open-label studies and drug court trials have been overwhelmingly successful," says Ryan Daniels of William Blair, which has done banking for Hythiam. Daniels, who rates Hythiam a buy, says licensees and clinical researchers express "strong satisfaction with, and belief in, the protocol." Donald Hooker of UBS (UBS ) (it did banking for Hythiam) says his buy rating, with a 12-month target of 15, is centered on "the clinical efficacy of PROMETA." Its stock doubled, from 4.77 in July to 10 on Jan. 12, before easing to 7.86 since the Feb. 27 market meltdown. "We are encouraged by the increasing evidence that PROMETA can change the paradigm of substance-abuse treatment," says Jack Silver, president of Siar Capital, which owns shares. |
|
Not yet rated
Rate now:
|
|
By:Tony Medina |
Date:04 03 07 |
volatility |
|
Not yet rated
Rate now:
|
|
By:gary hansen |
Date:01 18 07 |
looks good |
|
Not yet rated
Rate now:
|
|
By:david zazoff |
Date:01 05 07 |
could be worth $1 or $100 |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
| Comments not available |








